Objective: We tested the effects of a plant-based meal on these brain regions.

Methods: A randomized crossover design was used to test the effects of two energy- and macronutrient-matched meals: a vegan (V-meal) and a conventional (M-meal) on brain activity, gastrointestinal hormones, and satiety in participants with type 2 diabetes (T2D; n=20), overweight/obese participants (O; n=20), and healthy controls (H; n=20). Brain perfusion was measured, using arterial spin labeling functional brain imaging; satiety was assessed using a visual analogue scale; and plasma concentrations of gut hormones were determined at 0 and 180 min. Repeated-measures ANOVA was used for statistical analysis. Bonferroni correction for multiple comparisons was applied. The Hedge’s g statistic was used to measure the effect size for means of paired difference between the times (180-0 min) and meal types (M-V meal) for each group.

Results:Thalamus perfusion was the highest in patients with T2Dand the lowest in overweight individuals (p=0.001). Thalamus perfusion decreased significantly after ingestion of the M-meal in men with T2D (p=0.04) and overweight men (p=0.004), and it decreased significantly after ingestion of the V-meal in healthy controls (p<0.001). The effect size was -0.41 (95% CI, -1.14 to 0.31; p=0.26) for men with diabetes; -0.72 (95% CI, -1.48 to 0.01; p=0.05) for overweight/obese men; and 0.82 (95% CI, 0.09 to 1.59; p=0.03) for men with T2D. Changes in thalamus perfusion after ingestion of both test meals correlated with changes in satiety (r= +0.68; p<0.01), fasting plasma insulin (r= +0.40; p<0.01), C-peptide (r= +0.48; p<0.01) and amylin (r= +0.55; p<0.01), and insulin secretion at 5 mmol/l (r= +0.77; p<0.05).

Conclusion: Thalamus perfusion decreased after the M-meal in men with T2D and overweight/obese men, and it decreased after the V-meal in healthy controls. The changes in thalamus perfusion were associated with changes in satiety and insulin secretion.


H. Kahleova: None. M. Kudlackova: None. J. Tintera: None. L. Thieme: None. J. Veleba: None. H. Malinska: None. O. Oliyarnyk: None. I. Markova: None. M. Haluzik: Advisory Panel; Self; Lilly Diabetes, Sanofi. Consultant; Self; Ethicon US, LLC. Speaker’s Bureau; Self; AstraZeneca, Mundipharma International, Novartis AG, Novo Nordisk A/S. R. Pavlovicova: None. A. Tura: None. T. Pelikanova: None.


Ministry of Health of the Czech Republic (AZV15-27338A, IN00023001)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.